70岁以上早期乳腺癌患者前哨淋巴结活检的应用率及对辅助治疗的影响
本研究回顾性分析了2017至2019年间142例70岁以上、I-II期、临床淋巴结阴性、激素受体阳性且HER2阴性的乳腺癌患者,评估前哨淋巴结活检(SLNB)的使用率及其对辅助治疗的影响。结果显示83.1%的患者接受了SLNB,SLNB阳性与更高的辅助放疗率相关。
要点
- 尽管2016年指南不推荐,83.1%的70岁以上早期乳腺癌患者仍接受了SLNB。
- SLNB阳性患者接受局部辅助放疗的OR为4.66(95%CI 1.49-16.8)。
- 脉管浸润是SLNB阳性的主要危险因素(OR 13.4,95%CI 4.57-40.1)。
核心结论
- 在70岁以上符合指南豁免条件的早期乳腺癌患者中,SLNB使用率仍超过80%,且SLNB阳性与辅助放疗率增加相关。
研究设计与样本
- 回顾性分析2017至2019年间接受 upfront 手术的70岁以上、I-II期、临床淋巴结阴性、激素受体阳性、HER2阴性乳腺癌女性患者,共142例。
主要发现
- 118例(83.1%)接受了SLNB,其中27例(22.9%)SLNB阳性(N1mi 7例,N1a 20例)。
- 多因素回归显示,接受SLNB的患者更年轻(OR 0.87,95%CI 0.78-0.95)。
- SLNB阳性的主要危险因素是脉管浸润(OR 13.4,95%CI 4.57-40.1)。
- SLNB阳性患者更可能接受局部辅助放疗(OR 4.66,95%CI 1.49-16.8),且区域放疗比例更高(75.0% vs 15.3%,P < .001)。
关键数值与推荐
- 2016年SSO Choosing Wisely指南推荐:对于≥70岁、有利的早期乳腺癌患者,不常规进行SLNB。
- 本研究中SLNB阳性定义为N1mi(7例)或N1a(20例)。
临床怎么用
- 临床医生应认识到,尽管指南不推荐,高龄早期乳腺癌患者SLNB仍被广泛使用。
- SLNB阳性结果可能影响辅助放疗决策,需权衡放疗获益与风险。
- 对于有脉管浸润等高风险因素的患者,SLNB阳性可能性更高,应个体化决策。
局限性
- 回顾性单中心研究,样本量有限(142例)。
- 未报告SLNB对复发或生存结局的影响。
- 未分析未接受SLNB患者的特征及原因。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The 2016 Society of Surgical Oncology Choosing Wisely guidelines recommended against routine sentinel lymph node biopsy in women ≥70 years old with favorable, early-stage breast cancer, as sentinel lymph node biopsy does not decrease recurrence or mortality in these patients. This study's objective was to evaluate the use of sentinel lymph node biopsy and its effect on management in elderly patients. METHODS: A retrospective analysis of female patients ≥70 years old with stage I-II, clinically node-negative, hormone-receptor positive, HER2-negative disease undergoing upfront breast cancer surgery between 2017 and 2019. Primary outcome was rate of sentinel lymph node biopsy. Secondary outcome was effect of sentinel lymph node biopsy on adjuvant therapy. RESULTS: In total, 142 patients were included. Median age was 76 (interquartile range 73-81), and 71.8% underwent lumpectomy. On final pathology, 57.7% had invasive ductal carcinoma, and median tumor size was 15 mm (interquartile range 10-24.3). A total of 118 patients (83.1%) underwent sentinel lymph node biopsy; of these, 27 (22.9%) were positive for N1mi (7 patients) or N1a disease (20 patients). On multivariate regression analysis, patients undergoing sentinel lymph node biopsy were more likely to be younger (odds ratio 0.87, 95% confidence interval 0.78-0.95). The major risk factor for sentinel lymph node biopsy positivity was lymphovascular invasion (odds ratio 13.4, 95% confidence interval 4.57-40.1). Patients with sentinel lymph node biopsy positivity were more likely to receive local adjuvant radiation therapy (odds ratio 4.66, 95% confidence interval 1.49-16.8) and tended to receive more adjuvant regional radiation therapy (75.0% if sentinel lymph node biopsy positive compared with 15.3% if sentinel lymph node biopsy negative, P < .001). CONCLUSION: Despite the 2016 Choosing Wisely guidelines, more than 80% of patients ≥70 years old underwent sentinel lymph node biopsy at our institution. If sentinel lymph node biopsy was positive, this is associated with over 4-fold higher rates of adjuvant radiation therapy.
引用
- Di Lena É, Antoun A, Hopkins B, et al. Sentinel lymph node biopsy in women over 70: Evaluation of rates of axillary staging and impact on adjuvant therapy in elderly women. Surgery. 2022. PMID: 36372577. doi:10.1016/j.surg.2022.09.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。